Polio vaccination regimen shift to IPV followed by OPV instead of OPV alone debated at IoM/CDC conference.
Executive Summary
POLIO IMMUNIZATION WITH INACTIVATED AND LIVE VACCINES SHOULD REPLACE OPV, Samuel Katz, MD, Duke University, said at a June 8 Institute of Medicine/Centers for Disease Control & Prevention workshop on polio vaccines in Washington, D.C. In arguing for the change, Katz cited the estimated eight to 10 annual U.S. cases of vaccine-associated paralytic polio (VAPP) in people who have taken oral polio vaccine, and the three-year absence of the wild strain of polio from the Western hemisphere. "We have to show that we accept the fact that in a polio-free nation in a polio-free hemisphere we cannot have eight to 10 individuals paralyzed every year when there are alternatives," Katz said.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth